Category: Bayer HealthCareSyndicate content

Bayer: 5-year results confirm Essure's safety and effectiveness

May 4, 2015 by Brad Perriello

Bayer Healthcare cites 5-year data from a study of its Essure device as confirming the safety and effectiveness of the female sterilization procedure.

Bayer: 5-year results confirm Essure's safety and effectiveness

Valeritas sets terms for $75m IPO | Medtech Wall Street news for the week of March 9, 2015

March 12, 2015 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Diabetes: Valeritas sets terms for $75m IPO; New Siemens healthcare unit to start in May; Australia halts trading in GI Dynamics shares; Bayer aims to boost drugs sales, margins over next 3 years

Diabetes: Valeritas sets terms for $75m IPO

March 10, 2015 by Brad Perriello

Diabetes: Valeritas sets terms for $75m IPO

Bayer aims to boost drugs sales, margins over next 3 years

March 11, 2015 by MassDevice

Bayer says it plans to grow its main healthcare division by 6% annually over the next 3 years.

Bayer aims to boost drugs sales, margins over next 3 years

Olympus sold 'superbug' scopes without FDA clearance | Regulatory news for the week of March 9, 2015

March 10, 2015 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Olympus sold 'superbug' scopes without our clearance; FDA clears 1 Hospira plant, flags another; GI Dynamics plunges 50% after FDA halts trial; Sunshine Heart stops trial enrollment after patient deaths; Petition accuses Bayer's Conceptus of altering Essure trial data

FDA: Olympus sold 'superbug' scopes without our clearance

March 5, 2015 by Brad Perriello

Petition accuses Bayer's Conceptus of altering Essure trial data

March 9, 2015 by Brad Perriello

A citizens petition filed last month with the FDA accuses Bayer subsidiary Conceptus of altering the clinical trial data for its Essure female sterilization device to win pre-market approval from the safety watchdog.

Petition accuses Bayer's Conceptus of altering Essure trial data

UPDATED March 10, 2015, with comment from Bayer.

Report: Bayer may sell diabetes devices unit to KKR-backed Panasonic Health -report

February 20, 2015 by MassDevice

Is KKR-backed Panasonic Health a match for the long rumored sale of Bayer's diabetes device business?

Report: Bayer explores sale of diabetes device unit

(Reuters) - German drugmaker Bayer AG is close to selling its diabetes devices business to KKR-backed Panasonic Healthcare Holdings Co Ltd and the unit could be valued at up to $2.3 billion, Bloomberg news reported.

Report: Bayer explores sale of diabetes device unit

November 25, 2014 by MassDevice

Bayer is reportedly exploring a sale of its diabetes device business, which could fetch as much as $2.5 billion from interested private equity buyers.

Report: Bayer explores sale of diabetes device unit

(Reuters) — Bayer (PINK:BAYRY) is considering the sale of its diabetes device business, Bloomberg reported, citing sources.